VKTX241115C74000
- 0.05
- -0.15-75.00%
Viking Therapeutics Newsroom
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $164
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
10 Health Care Stocks With Whale Alerts In Today's Session
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Express News | Market news: Viking Therapeutics has achieved multiple endpoints in the Nash/Mash Phase 2B clinical trial results.
Viking Therapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024
Viking Therapeutics to Present Data From Phase 2b VOYAGE Study of VK2809 in Patients With Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
Peace Medical Acquired by Experienced Healthcare Professional, Ensuring Continuity and Growth
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
Viking Therapeutics (VKTX) Stock Surges on Promising Treatment Pipeline
Viking Therapeutics Offers An Obesity Drug for Healthy Adults
HC Wainwright & Co. Maintains Buy on Viking Therapeutics, Raises Price Target to $102
Viking Therapeutics Analyst Ratings
Daily short sale tracking: Viking Therapeutics's short volume increased by 3 million, with a short sale ratio of 14%
Viking Therapeutics(VKTX.US) ranked top of the list had the largest change in short volume (3.8 million shares), and the short volume ratio of Enbridge(ENB.US) reached 58.29%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $118
Social Buzz: Wallstreetbets Stocks Advance Premarket Tuesday; Palantir Technologies, Hims & Hers Health to Open Higher
Viking Therapeutics (VKTX.US) weight loss drug emerging unexpectedly, challenging the traditional leaders in the field.
The data released earlier on Monday by viking therapeutics on the weight-loss drug VK2735 indicates that novo-nordisk a/s and eli lilly and co, currently dominating the obesity drug market, may face fierce competition in the future.
Futu Morning Post | Countdown to the election! The panic index VIX is burning high and uncertainty is haunting the market nerves; Up nearly 13% after hours! Palantir raises full-year revenue guidance
Jpmorgan warns: If Trump wins on Wednesday, the Fed may pause the easing cycle as early as December; Will the US stock market hit new highs after the election? Jpmorgan: FOMO psychology boosts, S&P may hit 6100 points by the end of the year; US polls: Harris and Trump are neck and neck in key 'swing states'.